All In Biotech

Drug Trial Radar · NCT00271492

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

Endothelin in the Coronary Circulation in Early Atherosclerosis in Humans

Last checked: Nov 20, 2026Latest source record: Apr 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Jul 2001

Primary completion

Jun 2006

Study completion Jan 2008

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH)
First posted
Jan 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Qualifying patients who are scheduled for angiogram with endothelial function testing are approached to participate in this protocol (consent form reviewed with patient). Those who are willing to participate will have additional measurements taken during their angiogram as part of this protocol. Patients who are diagnosed with Endothelial Dysfunction as a result of a clinically indicated angiogram will be eligible to participate in a 6 month medication trial (Atrasentan vs. placebo - randomized, blinded trial). Patients are monitored closely during the 6 month trial via phone calls and blood testing for assessment. At the end of the 6 months they return to Mayo for a repeat angiogram to assess endothelial function for any changes or improvements.

Conditions

  • Endothelial Dysfunction

Interventions

  • AtrasentanDrug

    1 10mg capsule to be taken daily for 6 month study period.

  • AtrasentanDrug

    1 10mg capsule per day for the 6 month study period.

  • atrasentanDrug

    One 10 mg capsule per day for 6 month study period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To find out what effects (good and bad) the medication Atrasentan has on the heartTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.